Australia markets close in 6 hours 2 minutes

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
29.59-1.33 (-4.30%)
At close: 04:00PM EST
29.81 +0.22 (+0.74%)
After hours: 06:02PM EST
Full screen
Trade prices are not sourced from all markets
Previous close30.92
Bid29.57 x 1000
Ask29.81 x 1000
Day's range29.40 - 30.90
52-week range13.84 - 62.49
Avg. volume1,580,355
Market cap1.235B
Beta (5Y monthly)-0.02
PE ratio (TTM)N/A
EPS (TTM)-1.16
Earnings date27 Feb 2023 - 03 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend date13 Dec 2012
1y target est84.00
  • Motley Fool

    3 Big Reasons to Sell Cassava Sciences Stock Right Now

    On any list of biotech plays that might multiply in value in a relatively short period, Cassava Sciences (NASDAQ: SAVA) is likely to be near the top of the list. It's exploring whether its drug called simufilam is safe and effective to treat early-stage Alzheimer's disease, though its clinical trials have (so far) shed little light on the issue. The biggest reason to sell Cassava stock: After an open-label phase 2 clinical trial of simufilam, the market reacted quite negatively to the release of new data that management spun as being positive.

  • GlobeNewswire

    Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

    Figure 1 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, mild-to-moderate disease.¹ Figure 2 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, in early disease and mild disease.² ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets.47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 point

  • Zacks

    Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?

    Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.